Avid Bioservices, Inc. (CDMO) Report Analysis
Corporate Events
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 3000 Value Index
2022-06-24 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 3000 Value Index
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 2500 Value Index
2022-06-24 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 2500 Value Index
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell Small Cap Comp Value Index
2022-06-24 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell Small Cap Comp Value Index
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 2000 Value Index
2022-06-24 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 2000 Value Index
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 3000E Value Index
2022-06-24 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 3000E Value Index
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell Microcap Value Index
2022-06-24 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell Microcap Value Index
Avid Bioservices, Inc., Q4 2022 Earnings Call, Jun 29, 2022
2022-06-22 20:05:00
Avid Bioservices, Inc., Q4 2022 Earnings Call, Jun 29, 2022
Avid Bioservices, Inc. to Report Q4, 2022 Results on Jun 29, 2022
2022-06-22 20:05:00
Avid Bioservices, Inc. announced that they will report Q4, 2022 results After-Market on Jun 29, 2022
Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility
2022-06-14 12:05:00
Avid Bioservices, Inc. announced the opening of the analytical and process development (AD/PD) suites within the company’s new, world-class viral vector development and CGMP manufacturing facility. The launch of the AD/PD labs comes eight months to the day that Avid announced its intention to expand its CDMO service offering into the rapidly growing cell and gene therapy market. Build-out of the viral vector facility’s CGMP manufacturing suites is ongoing, with those capabilities expected to come online in mid-calendar 2023. The company’s new AD/PD labs are equipped with complete upstream, downstream and analytical development capabilities and are able to support up to 500 liter suspension culture in single-use bioreactors and various adherent cell modes. The company’s viral vector AD/PD team, which is led by Elie G. Hanania, Ph.D., has deep expertise in developing and implementing enabling technologies for viral vector production and purification processes focused on adeno-associated viruses (AAVs), lentiviruses, oncolytic viruses and other viruses for gene therapy and vaccine applications. In October 2022, Avid announced plans to construct a purpose-built 53,000 square foot viral vector facility in Costa Mesa, CA, approximately five miles from Avid’s existing operations in Tustin, CA. The strategic decision was driven by continued strong growth in the cell and gene therapy market combined with the CDMO industry’s overall lack of proven, high-quality CGMP manufacturing expertise and capacity for viral vectors. With more than 17 years of experience in commercial manufacturing of biologics underpinned by a strong quality ethos and a customer-centric approach to doing business, Avid offers a strong value proposition to prospective customers in the cell and gene therapy market.
Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business
2022-06-13 12:05:00
Avid Bioservices, Inc. announced that the company is further expanding its process development capacity for its mammalian cell business. As part of these efforts, Avid is expanding its laboratories which could support an additional $20 million in annual process development revenue, doubling the company's current process development capacity. The company estimates that this expansion will cost approximately $6 million and completion is anticipated by the end of calendar 2022. This expansion follows previous investments in increased process development capacity made in fiscal year 2019 and the most recent addition of high throughput capabilities in both upstream and downstream processing in fiscal year 2022. Process development represents a vital CDMO function and one through which Avid provides a critical advantage to customers in both early and late stages of development. This planned expansion further strengthens the company's capabilities in the areas of R&D support, process development, process characterization and validation, and pilot scale production for a broad range of mammalian cell-based biotechnology products. The new suites will further enhance Avid's ability to develop and deliver cost-effective, robust, scalable and compliant processes and to drive efficient and rapid on-boarding of new customer programs progressing to CGMP manufacturing.
Avid Bioservices, Inc. to Report Q2, 2022 Results on Dec 07, 2021
2021-11-30 21:05:00
Avid Bioservices, Inc. announced that they will report Q2, 2022 results After-Market on Dec 07, 2021
Avid Bioservices, Inc., Q2 2022 Earnings Call, Dec 07, 2021
2021-11-30 21:05:00
Avid Bioservices, Inc., Q2 2022 Earnings Call, Dec 07, 2021
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P 600
2021-10-29 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P 600
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P Composite 1500
2021-10-29 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P Composite 1500
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P 600 Health Care (Sector)
2021-10-29 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P 600 Health Care (Sector)
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P 1000
2021-10-29 00:00:00
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to S&P 1000
Avid Bioservices, Inc. - Shareholder/Analyst Call
2021-10-19 10:09:00
Shareholder Meeting
Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy
2021-10-14 12:05:00
Avid Bioservices, Inc. announced that the company is expanding its CDMO service offering into the rapidly growing cell and gene therapy market. As part of this effort, the company is constructing a world-class, purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA, approximately five miles from Avid’s existing operations in Tustin, CA. Additionally, Avid has appointed Drew Brennan, an experienced CDMO business development executive as general manager of viral vector technologies to lead its expansion into the cell and gene therapy market. Avid’s decision to expand its service offering into viral vector development and manufacturing is driven by continued strong growth in the cell and gene therapy market combined with the CDMO industry’s overall lack of proven, high-quality CGMP manufacturing expertise and capacity for viral vectors. With more than 16 years of experience in commercial manufacturing of biologics underpinned by a strong quality ethos and a customer-centric approach to doing business, Avid offers a strong value proposition to prospective customers in the cell and gene therapy market. Based on current projections, the company expects the entire new facility build out to take up to 18 months at an estimated cost of approximately $65 million to $75 million. The new facility’s analytical and process development laboratories are expected to come online more rapidly, with the potential to be operational within six-to-eight months. This investment into viral vector services follows Avid’s recent investments into growing its existing biologics manufacturing capacity through ongoing expansions at its Myford manufacturing facility. The expansion into viral vector services, combined with the addition of the potential annual revenue generating increases associated with the ongoing Myford expansion, has the potential to bring the company’s total annual revenue generating capacity to more than $350 million.
Avid Bioservices Appoints Drew Brennan as General Manager of Viral Vector Technologies
2021-10-14 12:05:00
Avid Bioservices, Inc. announced that the company is expanding its CDMO service offering into the rapidly growing cell and gene therapy market. Additionally, Avid has appointed Drew Brennan, an experienced CDMO business development executive as general manager of viral vector technologies to lead its expansion into the cell and gene therapy market. As newly appointed general manager of viral vector technologies, Mr. Brennan will be responsible for overseeing all business activities related to Avid’s expansion into the cell and gene therapy market. He most recently spent more than a decade in senior sales and operations positions at Novasep, a leading provider of equipment and services in the fields of both small molecule and biologics production and purification for the life science and chemical industries. His tenure at Novasep culminated in his serving as general manager for Novasep’s U.S. subsidiary, with responsibility for all products including viral vector CDMO services.
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
2021-10-07 12:05:00
Avid Bioservices, Inc. announced the appointment of Matthew Kwietniak as chief commercial officer. Mr. Kwietniak is an accomplished senior global sales executive with a proven track record of driving revenue growth and delivering sustainable results through the building and management of successful sales teams, as well as the establishment and expansion of key client relationships. In his new role, he will be responsible for continuing the current growth trajectory of Avid’s CDMO business through the ongoing expansion of the company’s commercial and clinical client base. Mr. Kwietniak most recently served as head of drug product sales for the Americas within the pharma services group at Thermo Fisher Scientific. In this role, he led the North America team of sales leaders and business development executives for the company’s pharmaceutical development and commercial manufacturing business. At Thermo Fisher Scientific, Mr. Kwietniak is credited with record sales growth and consistent overachievement of quarterly and annual goals during his tenure and leadership. He also spent over a decade as a senior sales executive in the clinical development services business at Covance, Inc., a division of LabCorp. Throughout his time with Covance, Mr. Kwietniak held multiple escalating sales leadership roles, culminating in a three-year tenure as executive director of sales in the clinical development services division. In this role, he expanded and managed a U.S. commercial team of business development directors that included the signing of several large Phase III contracts. In his leadership career, he has been responsible for growing and supporting sales teams generating in excess of $1 billion annually. Mr. Kwietniak has also achieved success in key sales manager and sales representative positions for VWR International (now Avantor).
Avid Bioservices, Inc. Reaffirms Revenue Guidance for the Full Year of 2022
2021-09-08 20:25:00
Avid Bioservices, Inc. reaffirmed revenue guidance for the full year of 2022. The company is confirming revenue guidance for the full fiscal year 2022 of $115 million to $117 million.
Avid Bioservices, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-09-04 18:06:00
Avid Bioservices, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.
Avid Bioservices, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 02:45 PM
2021-09-04 17:43:00
Avid Bioservices, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 02:45 PM. Venue: New Windsor, United States.
Avid Bioservices, Inc., Q1 2022 Earnings Call, Sep 08, 2021
2021-09-01 20:05:00
Avid Bioservices, Inc., Q1 2022 Earnings Call, Sep 08, 2021
Avid Bioservices, Inc. to Report Q1, 2022 Results on Sep 08, 2021
2021-09-01 20:05:00
Avid Bioservices, Inc. announced that they will report Q1, 2022 results After-Market on Sep 08, 2021
Avid Bioservices, Inc., Annual General Meeting, Oct 21, 2021
2021-08-27 21:22:00
Avid Bioservices, Inc., Annual General Meeting, Oct 21, 2021, at 10:00 Pacific Daylight. Location: 14191 Myford Road Tustin California United States Agenda: To elect seven directors to serve on the company's board of directors until 2022 annual meeting of stockholders, with each director to hold office until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal; to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the company for the fiscal year ending April 30, 2022; to approve, on an advisory basis, a non-binding resolution approving the compensation of the company’s named executive officers; to vote on an amendment to our 2018 Omnibus Incentive Plan to increase the shares reserved thereunder; and to conduct any other business properly brought before the 2021 annual meeting and any adjournment or postponement thereof.
Avid Bioservices, Inc. Announces Board Changes
2021-07-14 21:00:00
On July 8, 2021, Mr. Mark Bamforth notified the Board of Directors of Avid Bioservices, Inc. of his decision to resign, effective immediately, from his position as a member of the Board. Mr. Bamforth's resignation did not result from any disagreements with management or the Board on any matter relating to operations, policies or practice. Mr. Bamforth was chairman of the Board's corporate governance committee and a member of its audit committee at the time of his resignation. In connection with Mr. Bamforth's resignation, the Board has appointed Esther M. Alegria, Ph.D., as a member of the audit committee and corporate governance committee and appointed Joseph Carleone, Ph.D., as chairman of the corporate governance committee.
Avid Bioservices, Inc. Files with the Delaware Secretary of State A Restated Certificate of Incorporation That Combined into One Document the Company’s Certificate of Incorporation as Amended and Supplemented to Date
2021-07-07 20:30:00
On July 2, 2021, Avid Bioservices, Inc. filed with the Delaware Secretary of State a Restated Certificate of Incorporation that combined into one document the Company's Certificate of Incorporation as amended and supplemented to date. The Restated Certificate of Incorporation only restates and integrates, and does not further amend the provisions of the Certificate of Incorporation of the Company. The filing of the Restated Certificate of Incorporation on July 2, 2021 was authorized by the Board of Directors of the Company, in accordance with Section 245 of the Delaware General Corporation Law.
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
2021-07-01 12:05:00
Avid Bioservices, Inc. announced the appointment of Esther M. Alegria, Ph.D., as an independent member of the company’s board of directors. Dr. Alegria has nearly 30 years of biopharmaceutical industry experience spanning research and development, manufacturing, quality control, assurance and compliance, technology transfer and regulatory submissions supporting the development and commercialization of small and large molecule therapeutics and vaccines. Dr. Alegria currently serves as the chief executive officer of APIE Therapeutics.
Avid Bioservices, Inc. Provides Revenue Guidance for 2022
2021-06-29 20:05:00
Avid Bioservices, Inc. provided revenue guidance for 2022. For the period, the company expects revenue in the range of $115 million to $117 million.
Avid Bioservices, Inc. has filed a Shelf Registration.
2021-06-29 00:00:00
Avid Bioservices, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Security Name: Rights Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration
Fundamental Summary
Avid Bioservices published its Q4 report on 2022-03-08 with positive results, but no significant factors particularly remarkable relative to its peers. We do believe, though, that macro-related market conditions will influence its performance more significantly than its individual results. We therefore gave Avid Bioservices a total score of 69 out of 100 and a HOLD recommendation.
Avid Bioservices announced earnings results for the first quarter ended July 31, 2021. For the first quarter, the company announced sales was USD 30.754 million compared to USD 25.392 million a year ago. Operating income was USD 6.931 million compared to USD 4.719 million a year ago. Net income was USD 6.304 million compared to USD 4.730 million a year ago. Basic earnings per share from continuing operations was USD 0.1 compared to USD 0.06 a year ago.
Business Description
Avid Bioservices, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices in January 2018. Avid Bioservices was incorporated in 1981 and is headquartered in Tustin, California.
Sector Overview
Avid Bioservices is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Avid Bioservices's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 19.8 | -29.0% | 69 | |
| Net Cashflow | 79.1 | -38.2% | 80 | |
| Capital Expenditure | -36.0 | -92.4% | 40 | |
| Asset Turnover | 0.5 | -6.0% | 50 | |
| Free Cashflow | -0.2 | -281.7% | 38 |
* All values are TTM
The below chart reflects Avid Bioservices's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Avid Bioservices's peer average final assessment score stands on 65.0, Avid Bioservices's score is 69.
- CDMO
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Avid Bioservices's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Avid Bioservices's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.
5D MA
15.58
50D MA
13.86
200D MA
21.35
MACD
0.49
RSI
29.62
STOCH
81.12
Balance Sheet Analysis
Two main balance sheet metrics are driving the positive outlook for Avid Bioservices's financial strength going forward. In terms of liabilities, Avid Bioservices published good numbers. Their reported liabilities were 257.5, representing a 2.8% change from the previous report. These liabilities changes appear balanced compared to their peers and project the message that management is capable and focused on balancing asset growth, resource allocation, and growing liabilities. The company's liabilities movement component, therefore, received a grade of 75. Also, Avid Bioservices publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 20.2 and represents a -48.3% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. The company's book value factors component, therefore, received a grade of 72. However, one discouraging result, Cash & Equivalents, stood out. Avid Bioservices reported concerning cash and cash equivalents metrics in this filing. Specifically, they reported that cash and cash equivalents were 150.0, representing a -8.4% change from the last period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its cash and cash equivalents movement, therefore, received a grade of 58. Therefore, we scored its balance sheet a 67.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 314.1 | 4.1% | 61 |
| Liabilities | 257.5 | 2.8% | 75 |
| Price to Book | 20.2 | -48.3% | 72 |
| Cash & Equivalents | 150.0 | -8.4% | 58 |
| Equity | 56.6 | 10.7% | 61 |
The below chart describes Avid Bioservices's performance as reflected on its balance sheet with respect to its peers. While Avid Bioservices received a balance sheet score of 67, the average of its peers stands on 64.0.
- CDMO
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 2 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 3 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 4 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 5 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 7 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 8 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 16 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 20 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 21 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 22 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 24 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 33 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 35 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 37 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 41 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 43 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 45 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 51 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 59 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 63 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 65 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 74 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 87 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Overall, Avid Bioservices's critical income statement metrics appear to strongly support positive growth going forward. Avid Bioservices reported impressive EBITDA this period. At filing, EBITDA was reported as 26.4, representing 6.8% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 23.8%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Consequently, their EBITDA movement received a grade of 82. Also, In this filing, Avid Bioservices reported a return on equity (ROE) ratio of 19.8, which represents a change of -29.0%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 69. At the same time, one critical income statement metric, Revenue Efficiency, was notably weak. Avid Bioservices reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 116.0 and represented 9.1% change from the previous period. This metric might have a 12.9 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 49. Therefore, their income statement earned a grade of 75.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 26.4 | 6.8% | 82 |
| Total Revenues | 116.0 | 9.1% | 49 |
| Return on Equity | 19.8 | -29.0% | 69 |
The below chart describes Avid Bioservices's performance as reflected on its income statement with respect to its peers. While Avid Bioservices received a income statement score of 75 , the average of its peers stands on 69.0.
- CDMO
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 2 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 3 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 4 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 5 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 7 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 15 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 16 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 20 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 21 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 22 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 24 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 33 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 35 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 41 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 43 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 45 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 51 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 63 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 65 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 74 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 87 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 88 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Avid Bioservices appears likely to maintain its strong cash flow metrics and momentum going forward. Avid Bioservices's management was effective in improving their net cash flow, which now sits at 79.1 and represents a -38.2% change from the previous report. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 80. Also, Avid Bioservices is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.5, representing a -6.0% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 3.2 percent by this parameter. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. The company's asset turnover movement, therefore, received a grade of 50. That said, one metric, Free Cash flow, stood out as particularly concerning. Avid Bioservices's published free cash flow numbers were subpar and could mean that management has lost focus on achieving healthy growth. Avid Bioservices recorded free cash flow of -0.2, which represents -281.7% growth from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.8%. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Consequently, their free cash flow movement received a grade of 38. Consequently, their cash flow earned a score of 66.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 79.1 | -38.2% | 80 |
| Capital Expenditure | -36.0 | -92.4% | 40 |
| Asset Turnover | 0.5 | -6.0% | 50 |
| Free Cashflow | -0.2 | -281.7% | 38 |
The below chart describes Avid Bioservices's performance as reflected on its cash flow with respect to its peers. While Avid Bioservices received a cash flow score of 66, the average of its peers stands on 69.0.
- CDMO
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 2 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 3 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 4 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 5 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 7 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 16 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 20 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 21 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 22 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 24 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 33 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 35 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 41 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 43 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 45 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 51 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 63 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 65 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 74 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 87 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.